Anti-inflammatory effects of locally applied enzyme-loaded ultradeformable vesicles on an acute cutaneous model
Authors:
- Sandra SimõesSSSandra Simões
- Cláudia MarquesCMCláudia Marques
- Maria Eugénia CruzMCMaria Eugénia Cruz
- Maria Bárbara Figueira MartinsMMMaria Bárbara Figueira Martins
- 5 November 2009
- journal article
- research article
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 26 (7) , 649-658
Abstract
Superoxide dismutase (SOD) and catalase (CAT) are active scavengers of reactive oxygen species and were incorporated into ultradeformable vesicles with the aim of increasing enzyme bioavailability (skin delivery). These special very adaptable vesicles have been formulated and optimized for enzyme transport in order to penetrate into or across the intact skin barrier. Anti-inflammatory activity of SOD-loaded, CAT-loaded and of SOD- and CAT-loaded ultradeformable vesicles applied epicutaneously was measured using different protein doses on the skin, on an arachidonic acid-induced mouse ear oedema. The biological anti-oedema activity is a measurement of drug-targeting potentiation in the organ. Delivery by means of deformable vesicles was compared to conventional vesicles or the absence of an enzyme carrier mediated transport. This was done at various times following prophylactic application of the test formulations. Positive reference groups were treated epicutaneously with several low molecular weight non-steroidal anti-inflammatory drugs (NSAIDs). The latter included indomethacin (3 mg kg−1), etofenamate (30 mg kg−1) and piroxicam (1 mg kg−1) and reduced the oedema by 94 ± 4%, 81 ± 4% and 42 ± 5%, respectively, if measured 30 min after ear treatment with a NSAID. Of the enzyme-loaded carriers tested, only the enzyme-loaded ultradeformable vesicles reduced the swelling of ears significantly: SOD (90 µg kg−1), CAT (250 µg kg−1) and SOD (90 µg kg−1) plus CAT (250 µg kg−1) reduced the oedema by 70 ± 12%, 65 ± 10% and 61 ± 19%, respectively, at t = 30 min. Aqueous enzyme solutions and empty carriers had no such effect. The combination of two enzymes resulted in no increased therapeutic effect, but the results are inconclusive since only two dose combinations were tested. The results presented in this study suggest that antioxidant enzymes delivered by means of ultradeformable lipid vesicles can serve as a novel region-specific treatment of inflammation.Keywords
This publication has 41 references indexed in Scilit:
- Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trialAnnals of the Rheumatic Diseases, 2007
- Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SODJournal of Drug Targeting, 2006
- Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in TransfersomesJournal of Controlled Release, 2005
- Oral versus Topical NSAIDs in Rheumatic DiseasesDrugs, 2000
- Mechanisms of active oxygen species reduction by non-steroidal anti-inflammatory drugsThe International Journal of Biochemistry & Cell Biology, 1997
- Are the reactive oxygen-derived species (ROS) interactive properties of the many therapeutic drugs from various categories pertinent to their beneficial effects?General Pharmacology: The Vascular System, 1997
- The skin: a pathway for systemic treatment with patches and lipid-based agent carriersAdvanced Drug Delivery Reviews, 1996
- Dibenzoxepinone Hydroxylamines and Hydroxamic Acids: Dual Inhibitors of Cyclooxygenase and 5-Lipoxygenase with Potent Topical Antiinflammatory ActivityJournal of Medicinal Chemistry, 1996
- Clinical Pharmacokinetics and Delivery of Bovine Superoxide DismutaseClinical Pharmacokinetics, 1995
- Superoxide dismutase prevents lipid peroxidation in burned patientsBurns, 1990